Showing results (2691-2700 of 3,662) with videos related to

Sort By:
Pageof 367
Breast (Edinburgh, Scotland)|July 18, 2006
Schwannoma of the breast showing massive exophytic growth: a case reportE K Lee, S H Kook, H J Kwag, et al.
Breast (Edinburgh, Scotland)|May 14, 2026
Identifying pre-treatment risk factors for cancer-related cognitive decline in patients with breast cancerRob Colaes, Gwen Schroyen, Ahmed Radwan, et al.
Breast (Edinburgh, Scotland)|July 25, 2026
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastasesThomas Grinda, Hillary M Heiling, Nabihah Tayob, et al.
Breast (Edinburgh, Scotland)|July 14, 2026
Availability and public reimbursement of early breast cancer care across European expert centres: a PORTRAIT from an EUSOMA initiativeEduard-Alexandru Bonci, Rosa Di Micco, Lorenza Marotti, et al.
Breast (Edinburgh, Scotland)|August 10, 2026
Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLEKazuki Nozawa, Hiroji Iwata, Toru Mukohara, et al.
Breast (Edinburgh, Scotland)|August 10, 2026
Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registrySimon Peter Gampenrieder, Vanessa Castagnaviz, Rupert Bartsch, et al.
Breast (Edinburgh, Scotland)|August 11, 2026
Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older - final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE studyE Carola, P Caillet, C Falandry, et al.
Breast (Edinburgh, Scotland)|August 18, 2026
Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer - from feasibility to precision practiceYueting Tan, Benyuan Cheng, Kun He, et al.
Breast (Edinburgh, Scotland)|August 18, 2026
Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO databaseJ M Hannoun-Levi, J Gal, C Weltens, et al.
Breast (Edinburgh, Scotland)|August 22, 2026
Leveraging endocrine sensitivity in ER-positive DCIS: Neoadjuvant therapy and nonoperative managementRyoko Semba, Sarah Childs, Kate Saw, et al.
Pageof 367